Effects of Animal-assisted Therapy on the Physical Function and Communication of Adults With Autism

April 23, 2021 updated by: Daniel Collado-Mateo

Effects of Animal-assisted Therapy on the Physical Function and Communication of Adults With Autism: a Controlled Trial.

The aim is to evaluate the effects of a dog-assisted therapy program on physical function and communication in a sample comprised of 24 adults with autism spectrum disorder. The sample will be divided into 2 groups, a control group and an experimental group. Changes after 10 weeks (20 sessions) will be compared between-groups.

Study Overview

Status

Enrolling by invitation

Intervention / Treatment

Detailed Description

The intervention program will consist of 20 sessions conducted twice a week in the facilities of the collaborator associations. Each session will be conducted in groups of 3 participants and will last 30 minutes. It will include a welcome part, a main part (based on different activities and physical exercises with the dog) and a closing part to say goodbye to the dogs.

Physical function measures will be conducted before and after the completion of the study. The interaction and communication will be assessed during the sessions in the first, tenth and last ones.

Study Type

Interventional

Enrollment (Anticipated)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Madrid
      • Móstoles, Madrid, Spain, 28933
        • King Juan Carlos University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

36 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Older than 40 years
  • With autism spectrum disorder
  • Able to walk autonomously, without help from other people.
  • Able to climb and descent stairs autonomously, without help from other people.

Exclusion Criteria:

  • Medical condition that contraindicates the proximity or contact with the animals with the animals on the part of the user.
  • Allergy to dog epithelium.
  • Phobias to dogs.
  • History of aggression to animals.
  • Users who do not submit a signed informed consent form.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control group
Participants in this group will simply continue with their daily living and therapies. They will be assessed before and after the 10 week program but will not take part in it.
Experimental: Experimental group
Participants in this group will take part in the 20 session dog-assisted therapy. This therapy will be added to their usual daily living and therapies. They will be assessed before and after the 10 week program.
It will consist of 20 sessions conducted twice a week in the facilities of the association. It will involve different activities and physical exercises facilitated by the dogs. The program will be conducted in two associations (12 participants in each one, 6 belonging to the experimental and 6 belonging to the control group in each association) and in groups of three participants.
Other Names:
  • animal-assisted therapy
  • animal-assisted intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in walking performance (10m)
Time Frame: At baseline and inmediately after the intervention (within 7 days after the last session)
Evaluation of the ability to walk 10 meters in a corridor (time spent)
At baseline and inmediately after the intervention (within 7 days after the last session)
Changes in walking performance (6m)
Time Frame: At baseline and inmediately after the intervention (within 7 days after the last session)
Evaluation of the ability to walk 6 meters in a corridor (time spent)
At baseline and inmediately after the intervention (within 7 days after the last session)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in balance and risk of falling
Time Frame: At baseline and inmediately after the intervention (within 7 days after the last session)
Using the Tinetti Assessment Tool. Minimum score = 0. Maximum score for gait = 12 points; Maximum score for balance component = 16 points. Maximum total score = 28 points. Higher scores mean lower risk of falling.
At baseline and inmediately after the intervention (within 7 days after the last session)
Changes in communication without dog
Time Frame: At baseline and inmediately after the intervention (within 7 days after the last session)
An observation scale designed by the group to evaluate the interaction and communication with other people. It is comprised by 14 items, scored as 1 (yes) and 0 (no). Minimum score = 0; Maximum score = 14. Higher scores mean higher communication.
At baseline and inmediately after the intervention (within 7 days after the last session)
Changes in communication with dog
Time Frame: During sessions (first, intermediate and last one)
An observation scale designed by the group to evaluate the interaction and communication with the dogs and other people. It is comprised by 38 items, scored as 1 (yes) and 0 (no). Minimum score = 0; Maximum score = 38. Higher scores mean higher communication.
During sessions (first, intermediate and last one)
Changes in the ability to climb and descend stairs
Time Frame: At baseline and inmediately after the intervention (within 7 days after the last session)
Evaluation of the ability to climb and descend stairs (10 steps)
At baseline and inmediately after the intervention (within 7 days after the last session)
Changes in step length (6m)
Time Frame: At baseline and inmediately after the intervention (within 7 days after the last session)
Evaluation of the step length walking 6 meters in a corridor
At baseline and inmediately after the intervention (within 7 days after the last session)
Changes in step length (10m)
Time Frame: At baseline and inmediately after the intervention (within 7 days after the last session)
Evaluation of the step length walking 10 meters in a corridor
At baseline and inmediately after the intervention (within 7 days after the last session)
Changes in cadence (6m)
Time Frame: At baseline and inmediately after the intervention (within 7 days after the last session)
Evaluation of the cadence walking 6 meters in a corridor
At baseline and inmediately after the intervention (within 7 days after the last session)
Changes in cadence (10m)
Time Frame: At baseline and inmediately after the intervention (within 7 days after the last session)
Evaluation of the cadence walking 10 meters in a corridor
At baseline and inmediately after the intervention (within 7 days after the last session)
Changes in duration of phases in the gait cycle (6m)
Time Frame: At baseline and inmediately after the intervention (within 7 days after the last session)
Evaluation of the duration of phases in the gait cycle walking 6 meters in a corridor
At baseline and inmediately after the intervention (within 7 days after the last session)
Changes in duration of phases in the gait cycle (10m)
Time Frame: At baseline and inmediately after the intervention (within 7 days after the last session)
Evaluation of the duration of phases in the gait cycle walking 10 meters in a corridor
At baseline and inmediately after the intervention (within 7 days after the last session)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Daniel Collado-Mateo, PhD, Universidad Rey Juan Carlos

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

April 26, 2021

Primary Completion (Anticipated)

July 15, 2021

Study Completion (Anticipated)

July 15, 2021

Study Registration Dates

First Submitted

April 21, 2021

First Submitted That Met QC Criteria

April 23, 2021

First Posted (Actual)

April 26, 2021

Study Record Updates

Last Update Posted (Actual)

April 26, 2021

Last Update Submitted That Met QC Criteria

April 23, 2021

Last Verified

April 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Autism Spectrum Disorder

Clinical Trials on dog-assisted therapy

Subscribe